Oncolytic Viral Immunotherapy For Hard-To-Treat Solid Tumors

Time: 3:00 pm
day: Day Two

Details:

  • Introduction to oncolytic viral immunotherapy as a new approach to induce a specific immune response against the injected solid tumor and uninjected distant metastases
  • Clinical and immunological data showing the effects of experimental treatment with CAN-2409 in combination with immune checkpoint inhibitors (ICI) in patients with stage III/IV NSCLC who had an inadequate response to ICI as well treatment with CAN-2409 in combination with nivolumab and first-line standard of care in patients with high-grade glioma
  • Clinical and immunological data showing the effects of CAN-3110 in patients with recurrent high-grade glioma

Speakers: